nodes	percent_of_prediction	percent_of_DWPC	metapath
Fentanyl—prostate cancer—Hydrocortisone—psoriasis	0.245	0.45	CpDpCtD
Fentanyl—prostate cancer—Dexamethasone—psoriasis	0.15	0.275	CpDpCtD
Fentanyl—prostate cancer—Betamethasone—psoriasis	0.15	0.275	CpDpCtD
Fentanyl—CYP3A5—Beclomethasone—psoriasis	0.037	0.129	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0157	0.0549	CbGbCtD
Fentanyl—CYP3A7—Hydrocortisone—psoriasis	0.0157	0.0549	CbGbCtD
Fentanyl—CYP3A7—Cyclosporine—psoriasis	0.0149	0.0518	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0149	0.0518	CbGbCtD
Fentanyl—CYP3A5—Mycophenolate mofetil—psoriasis	0.0147	0.0513	CbGbCtD
Fentanyl—CYP3A4—Calcitriol—psoriasis	0.0128	0.0448	CbGbCtD
Fentanyl—CYP3A5—Hydrocortisone—psoriasis	0.0118	0.0411	CbGbCtD
Fentanyl—CYP3A5—Cyclosporine—psoriasis	0.0112	0.0389	CbGbCtD
Fentanyl—CYP3A4—Methoxsalen—psoriasis	0.00999	0.0348	CbGbCtD
Fentanyl—CYP3A7—Dexamethasone—psoriasis	0.00979	0.0341	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00979	0.0341	CbGbCtD
Fentanyl—ABCB1—Mycophenolate mofetil—psoriasis	0.00958	0.0334	CbGbCtD
Fentanyl—ABCB1—Betamethasone—psoriasis	0.00822	0.0286	CbGbCtD
Fentanyl—ABCB1—Prednisolone—psoriasis	0.00811	0.0282	CbGbCtD
Fentanyl—ABCB1—Hydrocortisone—psoriasis	0.00769	0.0268	CbGbCtD
Fentanyl—ABCB1—Prednisone—psoriasis	0.00766	0.0267	CbGbCtD
Fentanyl—CYP3A5—Dexamethasone—psoriasis	0.00734	0.0256	CbGbCtD
Fentanyl—ABCB1—Cyclosporine—psoriasis	0.00726	0.0253	CbGbCtD
Fentanyl—CYP3A4—Cholecalciferol—psoriasis	0.00662	0.0231	CbGbCtD
Fentanyl—CYP3A4—Mycophenolate mofetil—psoriasis	0.00574	0.02	CbGbCtD
Fentanyl—CYP3A4—Triamcinolone—psoriasis	0.00574	0.02	CbGbCtD
Fentanyl—CYP3A4—Betamethasone—psoriasis	0.00492	0.0172	CbGbCtD
Fentanyl—CYP3A4—Prednisolone—psoriasis	0.00486	0.0169	CbGbCtD
Fentanyl—ABCB1—Dexamethasone—psoriasis	0.00478	0.0167	CbGbCtD
Fentanyl—CYP3A4—Hydrocortisone—psoriasis	0.0046	0.016	CbGbCtD
Fentanyl—CYP3A4—Prednisone—psoriasis	0.00459	0.016	CbGbCtD
Fentanyl—CYP3A4—Cyclosporine—psoriasis	0.00435	0.0152	CbGbCtD
Fentanyl—ABCB1—Methotrexate—psoriasis	0.00384	0.0134	CbGbCtD
Fentanyl—CYP3A4—Dexamethasone—psoriasis	0.00286	0.00998	CbGbCtD
Fentanyl—Quinapril—ACE—psoriasis	0.000285	0.535	CrCbGaD
Fentanyl—Benazepril—ACE—psoriasis	0.000248	0.465	CrCbGaD
Fentanyl—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.000154	0.0768	CbGpPWpGaD
Fentanyl—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000111	0.0555	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL22—psoriasis	6.75e-05	0.0336	CbGpPWpGaD
Fentanyl—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	6.4e-05	0.0319	CbGpPWpGaD
Fentanyl—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	6.31e-05	0.0315	CbGpPWpGaD
Fentanyl—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	5.19e-05	0.0259	CbGpPWpGaD
Fentanyl—CYP3A4—Xenobiotics—CYP2S1—psoriasis	5.18e-05	0.0258	CbGpPWpGaD
Fentanyl—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	4.63e-05	0.0231	CbGpPWpGaD
Fentanyl—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	4.56e-05	0.0228	CbGpPWpGaD
Fentanyl—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	3.75e-05	0.0187	CbGpPWpGaD
Fentanyl—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	3.72e-05	0.0186	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	3.27e-05	0.0163	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	2.96e-05	0.0148	CbGpPWpGaD
Fentanyl—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	2.79e-05	0.0139	CbGpPWpGaD
Fentanyl—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	2.76e-05	0.0138	CbGpPWpGaD
Fentanyl—CYP3A7—Biological oxidations—CYP2S1—psoriasis	2.76e-05	0.0137	CbGpPWpGaD
Fentanyl—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	2.72e-05	0.0135	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—REL—psoriasis	2.67e-05	0.0133	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	2.6e-05	0.0129	CbGpPWpGaD
Fentanyl—Rash—Mycophenolic acid—psoriasis	2.33e-05	0.00014	CcSEcCtD
Fentanyl—Dermatitis—Mycophenolic acid—psoriasis	2.33e-05	0.00014	CcSEcCtD
Fentanyl—Pain—Prednisolone—psoriasis	2.33e-05	0.00014	CcSEcCtD
Fentanyl—Haemorrhage—Methotrexate—psoriasis	2.33e-05	0.00014	CcSEcCtD
Fentanyl—Urticaria—Mycophenolate mofetil—psoriasis	2.32e-05	0.00014	CcSEcCtD
Fentanyl—Headache—Mycophenolic acid—psoriasis	2.32e-05	0.000139	CcSEcCtD
Fentanyl—Decreased appetite—Hydrocortisone—psoriasis	2.31e-05	0.000139	CcSEcCtD
Fentanyl—Pharyngitis—Methotrexate—psoriasis	2.31e-05	0.000139	CcSEcCtD
Fentanyl—Body temperature increased—Mycophenolate mofetil—psoriasis	2.31e-05	0.000139	CcSEcCtD
Fentanyl—Abdominal pain—Mycophenolate mofetil—psoriasis	2.31e-05	0.000139	CcSEcCtD
Fentanyl—Urinary tract disorder—Methotrexate—psoriasis	2.3e-05	0.000138	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.29e-05	0.000138	CcSEcCtD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	2.29e-05	0.0114	CbGpPWpGaD
Fentanyl—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	2.29e-05	0.0114	CbGpPWpGaD
Fentanyl—Fatigue—Hydrocortisone—psoriasis	2.29e-05	0.000138	CcSEcCtD
Fentanyl—Vision blurred—Prednisone—psoriasis	2.28e-05	0.000138	CcSEcCtD
Fentanyl—Urethral disorder—Methotrexate—psoriasis	2.28e-05	0.000137	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.28e-05	0.000137	CcSEcCtD
Fentanyl—Pain—Hydrocortisone—psoriasis	2.27e-05	0.000137	CcSEcCtD
Fentanyl—Anaphylactic shock—Betamethasone—psoriasis	2.27e-05	0.000137	CcSEcCtD
Fentanyl—Anaphylactic shock—Dexamethasone—psoriasis	2.27e-05	0.000137	CcSEcCtD
Fentanyl—Oedema—Betamethasone—psoriasis	2.27e-05	0.000137	CcSEcCtD
Fentanyl—Oedema—Dexamethasone—psoriasis	2.27e-05	0.000137	CcSEcCtD
Fentanyl—Insomnia—Triamcinolone—psoriasis	2.26e-05	0.000136	CcSEcCtD
Fentanyl—Infection—Betamethasone—psoriasis	2.26e-05	0.000136	CcSEcCtD
Fentanyl—Infection—Dexamethasone—psoriasis	2.26e-05	0.000136	CcSEcCtD
Fentanyl—OPRD1—GPCR ligand binding—HCAR2—psoriasis	2.25e-05	0.0112	CbGpPWpGaD
Fentanyl—Ill-defined disorder—Prednisone—psoriasis	2.25e-05	0.000135	CcSEcCtD
Fentanyl—Paraesthesia—Triamcinolone—psoriasis	2.25e-05	0.000135	CcSEcCtD
Fentanyl—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	2.24e-05	0.0112	CbGpPWpGaD
Fentanyl—Feeling abnormal—Prednisolone—psoriasis	2.24e-05	0.000135	CcSEcCtD
Fentanyl—Visual impairment—Methotrexate—psoriasis	2.24e-05	0.000135	CcSEcCtD
Fentanyl—Anaemia—Prednisone—psoriasis	2.24e-05	0.000135	CcSEcCtD
Fentanyl—Shock—Betamethasone—psoriasis	2.23e-05	0.000135	CcSEcCtD
Fentanyl—Shock—Dexamethasone—psoriasis	2.23e-05	0.000135	CcSEcCtD
Fentanyl—Dyspnoea—Triamcinolone—psoriasis	2.23e-05	0.000134	CcSEcCtD
Fentanyl—Nervous system disorder—Betamethasone—psoriasis	2.23e-05	0.000134	CcSEcCtD
Fentanyl—Nervous system disorder—Dexamethasone—psoriasis	2.23e-05	0.000134	CcSEcCtD
Fentanyl—Agitation—Prednisone—psoriasis	2.23e-05	0.000134	CcSEcCtD
Fentanyl—Thrombocytopenia—Dexamethasone—psoriasis	2.22e-05	0.000134	CcSEcCtD
Fentanyl—Thrombocytopenia—Betamethasone—psoriasis	2.22e-05	0.000134	CcSEcCtD
Fentanyl—Tachycardia—Betamethasone—psoriasis	2.22e-05	0.000133	CcSEcCtD
Fentanyl—Tachycardia—Dexamethasone—psoriasis	2.22e-05	0.000133	CcSEcCtD
Fentanyl—Hypersensitivity—Cyclosporine—psoriasis	2.2e-05	0.000133	CcSEcCtD
Fentanyl—Dyspepsia—Triamcinolone—psoriasis	2.2e-05	0.000133	CcSEcCtD
Fentanyl—Erythema multiforme—Methotrexate—psoriasis	2.2e-05	0.000132	CcSEcCtD
Fentanyl—Nausea—Mycophenolic acid—psoriasis	2.2e-05	0.000132	CcSEcCtD
Fentanyl—Hyperhidrosis—Betamethasone—psoriasis	2.2e-05	0.000132	CcSEcCtD
Fentanyl—Hyperhidrosis—Dexamethasone—psoriasis	2.2e-05	0.000132	CcSEcCtD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	2.19e-05	0.0109	CbGpPWpGaD
Fentanyl—Feeling abnormal—Hydrocortisone—psoriasis	2.19e-05	0.000132	CcSEcCtD
Fentanyl—Malaise—Prednisone—psoriasis	2.19e-05	0.000132	CcSEcCtD
Fentanyl—Vertigo—Prednisone—psoriasis	2.18e-05	0.000131	CcSEcCtD
Fentanyl—Eye disorder—Methotrexate—psoriasis	2.17e-05	0.000131	CcSEcCtD
Fentanyl—Gastrointestinal pain—Hydrocortisone—psoriasis	2.17e-05	0.000131	CcSEcCtD
Fentanyl—Syncope—Prednisone—psoriasis	2.17e-05	0.000131	CcSEcCtD
Fentanyl—Tinnitus—Methotrexate—psoriasis	2.17e-05	0.000131	CcSEcCtD
Fentanyl—Anorexia—Betamethasone—psoriasis	2.16e-05	0.00013	CcSEcCtD
Fentanyl—Anorexia—Dexamethasone—psoriasis	2.16e-05	0.00013	CcSEcCtD
Fentanyl—Urticaria—Prednisolone—psoriasis	2.16e-05	0.00013	CcSEcCtD
Fentanyl—Cardiac disorder—Methotrexate—psoriasis	2.16e-05	0.00013	CcSEcCtD
Fentanyl—Fatigue—Triamcinolone—psoriasis	2.16e-05	0.00013	CcSEcCtD
Fentanyl—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	2.15e-05	0.0107	CbGpPWpGaD
Fentanyl—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.15e-05	0.000129	CcSEcCtD
Fentanyl—Asthenia—Cyclosporine—psoriasis	2.15e-05	0.000129	CcSEcCtD
Fentanyl—Pain—Triamcinolone—psoriasis	2.14e-05	0.000129	CcSEcCtD
Fentanyl—Loss of consciousness—Prednisone—psoriasis	2.13e-05	0.000128	CcSEcCtD
Fentanyl—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	2.12e-05	0.0106	CbGpPWpGaD
Fentanyl—Hypotension—Dexamethasone—psoriasis	2.12e-05	0.000128	CcSEcCtD
Fentanyl—Hypotension—Betamethasone—psoriasis	2.12e-05	0.000128	CcSEcCtD
Fentanyl—Pruritus—Cyclosporine—psoriasis	2.12e-05	0.000127	CcSEcCtD
Fentanyl—Urticaria—Hydrocortisone—psoriasis	2.11e-05	0.000127	CcSEcCtD
Fentanyl—Angiopathy—Methotrexate—psoriasis	2.11e-05	0.000127	CcSEcCtD
Fentanyl—Immune system disorder—Methotrexate—psoriasis	2.1e-05	0.000127	CcSEcCtD
Fentanyl—Abdominal pain—Hydrocortisone—psoriasis	2.1e-05	0.000127	CcSEcCtD
Fentanyl—Body temperature increased—Hydrocortisone—psoriasis	2.1e-05	0.000127	CcSEcCtD
Fentanyl—Convulsion—Prednisone—psoriasis	2.1e-05	0.000126	CcSEcCtD
Fentanyl—Mediastinal disorder—Methotrexate—psoriasis	2.1e-05	0.000126	CcSEcCtD
Fentanyl—Asthenia—Mycophenolate mofetil—psoriasis	2.09e-05	0.000126	CcSEcCtD
Fentanyl—Hypertension—Prednisone—psoriasis	2.09e-05	0.000126	CcSEcCtD
Fentanyl—Chills—Methotrexate—psoriasis	2.09e-05	0.000126	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Betamethasone—psoriasis	2.07e-05	0.000125	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.07e-05	0.000125	CcSEcCtD
Fentanyl—Pruritus—Mycophenolate mofetil—psoriasis	2.06e-05	0.000124	CcSEcCtD
Fentanyl—Arthralgia—Prednisone—psoriasis	2.06e-05	0.000124	CcSEcCtD
Fentanyl—Myalgia—Prednisone—psoriasis	2.06e-05	0.000124	CcSEcCtD
Fentanyl—Feeling abnormal—Triamcinolone—psoriasis	2.06e-05	0.000124	CcSEcCtD
Fentanyl—Anxiety—Prednisone—psoriasis	2.06e-05	0.000124	CcSEcCtD
Fentanyl—OPRM1—IL4-mediated signaling events—IL10—psoriasis	2.06e-05	0.0102	CbGpPWpGaD
Fentanyl—Alopecia—Methotrexate—psoriasis	2.06e-05	0.000124	CcSEcCtD
Fentanyl—Insomnia—Betamethasone—psoriasis	2.05e-05	0.000124	CcSEcCtD
Fentanyl—Insomnia—Dexamethasone—psoriasis	2.05e-05	0.000124	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.05e-05	0.000123	CcSEcCtD
Fentanyl—Diarrhoea—Cyclosporine—psoriasis	2.05e-05	0.000123	CcSEcCtD
Fentanyl—Paraesthesia—Dexamethasone—psoriasis	2.04e-05	0.000123	CcSEcCtD
Fentanyl—Paraesthesia—Betamethasone—psoriasis	2.04e-05	0.000123	CcSEcCtD
Fentanyl—Discomfort—Prednisone—psoriasis	2.04e-05	0.000123	CcSEcCtD
Fentanyl—Mental disorder—Methotrexate—psoriasis	2.04e-05	0.000123	CcSEcCtD
Fentanyl—Erythema—Methotrexate—psoriasis	2.03e-05	0.000122	CcSEcCtD
Fentanyl—Malnutrition—Methotrexate—psoriasis	2.03e-05	0.000122	CcSEcCtD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	2.01e-05	0.01	CbGpPWpGaD
Fentanyl—Hypersensitivity—Prednisolone—psoriasis	2.01e-05	0.000121	CcSEcCtD
Fentanyl—OPRM1—IL4-mediated signaling events—IL4—psoriasis	2e-05	0.00997	CbGpPWpGaD
Fentanyl—Dyspepsia—Dexamethasone—psoriasis	2e-05	0.00012	CcSEcCtD
Fentanyl—Dyspepsia—Betamethasone—psoriasis	2e-05	0.00012	CcSEcCtD
Fentanyl—Diarrhoea—Mycophenolate mofetil—psoriasis	2e-05	0.00012	CcSEcCtD
Fentanyl—CYP3A5—Biological oxidations—CYP2S1—psoriasis	1.99e-05	0.00993	CbGpPWpGaD
Fentanyl—Urticaria—Triamcinolone—psoriasis	1.99e-05	0.00012	CcSEcCtD
Fentanyl—Dysgeusia—Methotrexate—psoriasis	1.98e-05	0.000119	CcSEcCtD
Fentanyl—Body temperature increased—Triamcinolone—psoriasis	1.98e-05	0.000119	CcSEcCtD
Fentanyl—Dizziness—Cyclosporine—psoriasis	1.98e-05	0.000119	CcSEcCtD
Fentanyl—Anaphylactic shock—Prednisone—psoriasis	1.98e-05	0.000119	CcSEcCtD
Fentanyl—Oedema—Prednisone—psoriasis	1.98e-05	0.000119	CcSEcCtD
Fentanyl—OPRK1—GPCR ligand binding—HCAR2—psoriasis	1.98e-05	0.00985	CbGpPWpGaD
Fentanyl—Decreased appetite—Dexamethasone—psoriasis	1.97e-05	0.000119	CcSEcCtD
Fentanyl—Decreased appetite—Betamethasone—psoriasis	1.97e-05	0.000119	CcSEcCtD
Fentanyl—Infection—Prednisone—psoriasis	1.96e-05	0.000118	CcSEcCtD
Fentanyl—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	1.96e-05	0.00979	CbGpPWpGaD
Fentanyl—Gastrointestinal disorder—Dexamethasone—psoriasis	1.96e-05	0.000118	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Betamethasone—psoriasis	1.96e-05	0.000118	CcSEcCtD
Fentanyl—Back pain—Methotrexate—psoriasis	1.96e-05	0.000118	CcSEcCtD
Fentanyl—Hypersensitivity—Hydrocortisone—psoriasis	1.96e-05	0.000118	CcSEcCtD
Fentanyl—Fatigue—Betamethasone—psoriasis	1.96e-05	0.000118	CcSEcCtD
Fentanyl—Fatigue—Dexamethasone—psoriasis	1.96e-05	0.000118	CcSEcCtD
Fentanyl—Shock—Prednisone—psoriasis	1.95e-05	0.000117	CcSEcCtD
Fentanyl—Pain—Betamethasone—psoriasis	1.94e-05	0.000117	CcSEcCtD
Fentanyl—Pain—Dexamethasone—psoriasis	1.94e-05	0.000117	CcSEcCtD
Fentanyl—Nervous system disorder—Prednisone—psoriasis	1.94e-05	0.000117	CcSEcCtD
Fentanyl—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	1.93e-05	0.00964	CbGpPWpGaD
Fentanyl—Tachycardia—Prednisone—psoriasis	1.93e-05	0.000116	CcSEcCtD
Fentanyl—Dizziness—Mycophenolate mofetil—psoriasis	1.93e-05	0.000116	CcSEcCtD
Fentanyl—Skin disorder—Prednisone—psoriasis	1.92e-05	0.000116	CcSEcCtD
Fentanyl—Hyperhidrosis—Prednisone—psoriasis	1.91e-05	0.000115	CcSEcCtD
Fentanyl—Vision blurred—Methotrexate—psoriasis	1.91e-05	0.000115	CcSEcCtD
Fentanyl—Asthenia—Hydrocortisone—psoriasis	1.91e-05	0.000115	CcSEcCtD
Fentanyl—Vomiting—Cyclosporine—psoriasis	1.9e-05	0.000115	CcSEcCtD
Fentanyl—Rash—Cyclosporine—psoriasis	1.89e-05	0.000114	CcSEcCtD
Fentanyl—Anorexia—Prednisone—psoriasis	1.89e-05	0.000114	CcSEcCtD
Fentanyl—Dermatitis—Cyclosporine—psoriasis	1.88e-05	0.000113	CcSEcCtD
Fentanyl—Pruritus—Hydrocortisone—psoriasis	1.88e-05	0.000113	CcSEcCtD
Fentanyl—Ill-defined disorder—Methotrexate—psoriasis	1.88e-05	0.000113	CcSEcCtD
Fentanyl—Headache—Cyclosporine—psoriasis	1.87e-05	0.000113	CcSEcCtD
Fentanyl—Anaemia—Methotrexate—psoriasis	1.87e-05	0.000113	CcSEcCtD
Fentanyl—Feeling abnormal—Dexamethasone—psoriasis	1.87e-05	0.000113	CcSEcCtD
Fentanyl—Feeling abnormal—Betamethasone—psoriasis	1.87e-05	0.000113	CcSEcCtD
Fentanyl—Gastrointestinal pain—Betamethasone—psoriasis	1.86e-05	0.000112	CcSEcCtD
Fentanyl—Gastrointestinal pain—Dexamethasone—psoriasis	1.86e-05	0.000112	CcSEcCtD
Fentanyl—Vomiting—Mycophenolate mofetil—psoriasis	1.86e-05	0.000112	CcSEcCtD
Fentanyl—Hypersensitivity—Triamcinolone—psoriasis	1.84e-05	0.000111	CcSEcCtD
Fentanyl—Rash—Mycophenolate mofetil—psoriasis	1.84e-05	0.000111	CcSEcCtD
Fentanyl—Dermatitis—Mycophenolate mofetil—psoriasis	1.84e-05	0.000111	CcSEcCtD
Fentanyl—Headache—Mycophenolate mofetil—psoriasis	1.83e-05	0.00011	CcSEcCtD
Fentanyl—Malaise—Methotrexate—psoriasis	1.83e-05	0.00011	CcSEcCtD
Fentanyl—Vertigo—Methotrexate—psoriasis	1.82e-05	0.00011	CcSEcCtD
Fentanyl—Diarrhoea—Hydrocortisone—psoriasis	1.82e-05	0.00011	CcSEcCtD
Fentanyl—Leukopenia—Methotrexate—psoriasis	1.81e-05	0.000109	CcSEcCtD
Fentanyl—Urticaria—Betamethasone—psoriasis	1.8e-05	0.000109	CcSEcCtD
Fentanyl—Urticaria—Dexamethasone—psoriasis	1.8e-05	0.000109	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Prednisone—psoriasis	1.8e-05	0.000108	CcSEcCtD
Fentanyl—Dizziness—Prednisolone—psoriasis	1.8e-05	0.000108	CcSEcCtD
Fentanyl—Asthenia—Triamcinolone—psoriasis	1.8e-05	0.000108	CcSEcCtD
Fentanyl—Body temperature increased—Dexamethasone—psoriasis	1.8e-05	0.000108	CcSEcCtD
Fentanyl—Abdominal pain—Betamethasone—psoriasis	1.8e-05	0.000108	CcSEcCtD
Fentanyl—Abdominal pain—Dexamethasone—psoriasis	1.8e-05	0.000108	CcSEcCtD
Fentanyl—Body temperature increased—Betamethasone—psoriasis	1.8e-05	0.000108	CcSEcCtD
Fentanyl—Insomnia—Prednisone—psoriasis	1.79e-05	0.000108	CcSEcCtD
Fentanyl—Nausea—Cyclosporine—psoriasis	1.78e-05	0.000107	CcSEcCtD
Fentanyl—Paraesthesia—Prednisone—psoriasis	1.78e-05	0.000107	CcSEcCtD
Fentanyl—Pruritus—Triamcinolone—psoriasis	1.77e-05	0.000107	CcSEcCtD
Fentanyl—Cough—Methotrexate—psoriasis	1.77e-05	0.000106	CcSEcCtD
Fentanyl—Dizziness—Hydrocortisone—psoriasis	1.76e-05	0.000106	CcSEcCtD
Fentanyl—Convulsion—Methotrexate—psoriasis	1.75e-05	0.000106	CcSEcCtD
Fentanyl—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	1.74e-05	0.00869	CbGpPWpGaD
Fentanyl—Dyspepsia—Prednisone—psoriasis	1.74e-05	0.000105	CcSEcCtD
Fentanyl—Nausea—Mycophenolate mofetil—psoriasis	1.73e-05	0.000104	CcSEcCtD
Fentanyl—Chest pain—Methotrexate—psoriasis	1.72e-05	0.000104	CcSEcCtD
Fentanyl—Myalgia—Methotrexate—psoriasis	1.72e-05	0.000104	CcSEcCtD
Fentanyl—Arthralgia—Methotrexate—psoriasis	1.72e-05	0.000104	CcSEcCtD
Fentanyl—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	1.72e-05	0.00857	CbGpPWpGaD
Fentanyl—Decreased appetite—Prednisone—psoriasis	1.72e-05	0.000104	CcSEcCtD
Fentanyl—Rash—Prednisolone—psoriasis	1.72e-05	0.000103	CcSEcCtD
Fentanyl—Dermatitis—Prednisolone—psoriasis	1.71e-05	0.000103	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.71e-05	0.000103	CcSEcCtD
Fentanyl—Fatigue—Prednisone—psoriasis	1.71e-05	0.000103	CcSEcCtD
Fentanyl—Headache—Prednisolone—psoriasis	1.71e-05	0.000103	CcSEcCtD
Fentanyl—Discomfort—Methotrexate—psoriasis	1.7e-05	0.000103	CcSEcCtD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	1.7e-05	0.00847	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	1.7e-05	0.00845	CbGpPWpGaD
Fentanyl—Constipation—Prednisone—psoriasis	1.69e-05	0.000102	CcSEcCtD
Fentanyl—Vomiting—Hydrocortisone—psoriasis	1.69e-05	0.000102	CcSEcCtD
Fentanyl—Rash—Hydrocortisone—psoriasis	1.68e-05	0.000101	CcSEcCtD
Fentanyl—Dermatitis—Hydrocortisone—psoriasis	1.67e-05	0.000101	CcSEcCtD
Fentanyl—OPRM1—GPCR ligand binding—HCAR2—psoriasis	1.67e-05	0.00833	CbGpPWpGaD
Fentanyl—Confusional state—Methotrexate—psoriasis	1.67e-05	0.0001	CcSEcCtD
Fentanyl—Headache—Hydrocortisone—psoriasis	1.67e-05	0.0001	CcSEcCtD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	1.66e-05	0.00825	CbGpPWpGaD
Fentanyl—Dizziness—Triamcinolone—psoriasis	1.66e-05	9.97e-05	CcSEcCtD
Fentanyl—Anaphylactic shock—Methotrexate—psoriasis	1.65e-05	9.95e-05	CcSEcCtD
Fentanyl—Infection—Methotrexate—psoriasis	1.64e-05	9.89e-05	CcSEcCtD
Fentanyl—Feeling abnormal—Prednisone—psoriasis	1.63e-05	9.81e-05	CcSEcCtD
Fentanyl—Asthenia—Betamethasone—psoriasis	1.63e-05	9.81e-05	CcSEcCtD
Fentanyl—Asthenia—Dexamethasone—psoriasis	1.63e-05	9.81e-05	CcSEcCtD
Fentanyl—Nervous system disorder—Methotrexate—psoriasis	1.62e-05	9.76e-05	CcSEcCtD
Fentanyl—Thrombocytopenia—Methotrexate—psoriasis	1.62e-05	9.74e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Prednisone—psoriasis	1.62e-05	9.74e-05	CcSEcCtD
Fentanyl—Nausea—Prednisolone—psoriasis	1.62e-05	9.73e-05	CcSEcCtD
Fentanyl—Pruritus—Betamethasone—psoriasis	1.61e-05	9.67e-05	CcSEcCtD
Fentanyl—Pruritus—Dexamethasone—psoriasis	1.61e-05	9.67e-05	CcSEcCtD
Fentanyl—Skin disorder—Methotrexate—psoriasis	1.61e-05	9.67e-05	CcSEcCtD
Fentanyl—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	1.6e-05	0.00799	CbGpPWpGaD
Fentanyl—Hyperhidrosis—Methotrexate—psoriasis	1.6e-05	9.62e-05	CcSEcCtD
Fentanyl—Vomiting—Triamcinolone—psoriasis	1.59e-05	9.58e-05	CcSEcCtD
Fentanyl—Nausea—Hydrocortisone—psoriasis	1.58e-05	9.51e-05	CcSEcCtD
Fentanyl—Rash—Triamcinolone—psoriasis	1.58e-05	9.5e-05	CcSEcCtD
Fentanyl—Dermatitis—Triamcinolone—psoriasis	1.58e-05	9.49e-05	CcSEcCtD
Fentanyl—Anorexia—Methotrexate—psoriasis	1.58e-05	9.49e-05	CcSEcCtD
Fentanyl—Urticaria—Prednisone—psoriasis	1.57e-05	9.46e-05	CcSEcCtD
Fentanyl—Headache—Triamcinolone—psoriasis	1.57e-05	9.44e-05	CcSEcCtD
Fentanyl—Abdominal pain—Prednisone—psoriasis	1.56e-05	9.41e-05	CcSEcCtD
Fentanyl—Body temperature increased—Prednisone—psoriasis	1.56e-05	9.41e-05	CcSEcCtD
Fentanyl—Diarrhoea—Dexamethasone—psoriasis	1.55e-05	9.36e-05	CcSEcCtD
Fentanyl—Diarrhoea—Betamethasone—psoriasis	1.55e-05	9.36e-05	CcSEcCtD
Fentanyl—Hypotension—Methotrexate—psoriasis	1.54e-05	9.3e-05	CcSEcCtD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	1.54e-05	0.00767	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	1.51e-05	0.00752	CbGpPWpGaD
Fentanyl—Musculoskeletal discomfort—Methotrexate—psoriasis	1.51e-05	9.07e-05	CcSEcCtD
Fentanyl—Dizziness—Dexamethasone—psoriasis	1.5e-05	9.04e-05	CcSEcCtD
Fentanyl—Dizziness—Betamethasone—psoriasis	1.5e-05	9.04e-05	CcSEcCtD
Fentanyl—Insomnia—Methotrexate—psoriasis	1.49e-05	9e-05	CcSEcCtD
Fentanyl—Nausea—Triamcinolone—psoriasis	1.49e-05	8.95e-05	CcSEcCtD
Fentanyl—Paraesthesia—Methotrexate—psoriasis	1.48e-05	8.94e-05	CcSEcCtD
Fentanyl—Dyspnoea—Methotrexate—psoriasis	1.47e-05	8.87e-05	CcSEcCtD
Fentanyl—Somnolence—Methotrexate—psoriasis	1.47e-05	8.85e-05	CcSEcCtD
Fentanyl—Hypersensitivity—Prednisone—psoriasis	1.46e-05	8.77e-05	CcSEcCtD
Fentanyl—Dyspepsia—Methotrexate—psoriasis	1.45e-05	8.76e-05	CcSEcCtD
Fentanyl—Vomiting—Dexamethasone—psoriasis	1.44e-05	8.69e-05	CcSEcCtD
Fentanyl—Vomiting—Betamethasone—psoriasis	1.44e-05	8.69e-05	CcSEcCtD
Fentanyl—Decreased appetite—Methotrexate—psoriasis	1.44e-05	8.65e-05	CcSEcCtD
Fentanyl—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	1.43e-05	0.00715	CbGpPWpGaD
Fentanyl—Rash—Betamethasone—psoriasis	1.43e-05	8.62e-05	CcSEcCtD
Fentanyl—Rash—Dexamethasone—psoriasis	1.43e-05	8.62e-05	CcSEcCtD
Fentanyl—Dermatitis—Dexamethasone—psoriasis	1.43e-05	8.61e-05	CcSEcCtD
Fentanyl—Dermatitis—Betamethasone—psoriasis	1.43e-05	8.61e-05	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Methotrexate—psoriasis	1.43e-05	8.59e-05	CcSEcCtD
Fentanyl—Fatigue—Methotrexate—psoriasis	1.43e-05	8.58e-05	CcSEcCtD
Fentanyl—Headache—Dexamethasone—psoriasis	1.42e-05	8.57e-05	CcSEcCtD
Fentanyl—Headache—Betamethasone—psoriasis	1.42e-05	8.57e-05	CcSEcCtD
Fentanyl—Asthenia—Prednisone—psoriasis	1.42e-05	8.54e-05	CcSEcCtD
Fentanyl—Pain—Methotrexate—psoriasis	1.41e-05	8.51e-05	CcSEcCtD
Fentanyl—Pruritus—Prednisone—psoriasis	1.4e-05	8.43e-05	CcSEcCtD
Fentanyl—Feeling abnormal—Methotrexate—psoriasis	1.36e-05	8.2e-05	CcSEcCtD
Fentanyl—Diarrhoea—Prednisone—psoriasis	1.35e-05	8.15e-05	CcSEcCtD
Fentanyl—Gastrointestinal pain—Methotrexate—psoriasis	1.35e-05	8.14e-05	CcSEcCtD
Fentanyl—Nausea—Betamethasone—psoriasis	1.35e-05	8.12e-05	CcSEcCtD
Fentanyl—Nausea—Dexamethasone—psoriasis	1.35e-05	8.12e-05	CcSEcCtD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	1.35e-05	0.00672	CbGpPWpGaD
Fentanyl—Urticaria—Methotrexate—psoriasis	1.31e-05	7.91e-05	CcSEcCtD
Fentanyl—Dizziness—Prednisone—psoriasis	1.31e-05	7.88e-05	CcSEcCtD
Fentanyl—Abdominal pain—Methotrexate—psoriasis	1.31e-05	7.87e-05	CcSEcCtD
Fentanyl—Body temperature increased—Methotrexate—psoriasis	1.31e-05	7.87e-05	CcSEcCtD
Fentanyl—ABCB1—Allograft Rejection—HLA-C—psoriasis	1.28e-05	0.00637	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	1.27e-05	0.00635	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL13—psoriasis	1.27e-05	0.00633	CbGpPWpGaD
Fentanyl—Vomiting—Prednisone—psoriasis	1.26e-05	7.57e-05	CcSEcCtD
Fentanyl—Rash—Prednisone—psoriasis	1.25e-05	7.51e-05	CcSEcCtD
Fentanyl—Dermatitis—Prednisone—psoriasis	1.25e-05	7.5e-05	CcSEcCtD
Fentanyl—Headache—Prednisone—psoriasis	1.24e-05	7.46e-05	CcSEcCtD
Fentanyl—Hypersensitivity—Methotrexate—psoriasis	1.22e-05	7.33e-05	CcSEcCtD
Fentanyl—Asthenia—Methotrexate—psoriasis	1.19e-05	7.14e-05	CcSEcCtD
Fentanyl—Nausea—Prednisone—psoriasis	1.17e-05	7.07e-05	CcSEcCtD
Fentanyl—OPRD1—GPCR ligand binding—CCL20—psoriasis	1.17e-05	0.00584	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	1.17e-05	0.00583	CbGpPWpGaD
Fentanyl—Pruritus—Methotrexate—psoriasis	1.17e-05	7.04e-05	CcSEcCtD
Fentanyl—ABCB1—Allograft Rejection—IL17A—psoriasis	1.17e-05	0.00583	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—HCAR2—psoriasis	1.16e-05	0.00577	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	1.14e-05	0.00568	CbGpPWpGaD
Fentanyl—Diarrhoea—Methotrexate—psoriasis	1.13e-05	6.81e-05	CcSEcCtD
Fentanyl—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.12e-05	0.00557	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	1.12e-05	0.00557	CbGpPWpGaD
Fentanyl—Dizziness—Methotrexate—psoriasis	1.09e-05	6.58e-05	CcSEcCtD
Fentanyl—ABCB1—Allograft Rejection—IL12B—psoriasis	1.09e-05	0.00542	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—HLA-E—psoriasis	1.06e-05	0.00529	CbGpPWpGaD
Fentanyl—Vomiting—Methotrexate—psoriasis	1.05e-05	6.33e-05	CcSEcCtD
Fentanyl—Rash—Methotrexate—psoriasis	1.04e-05	6.28e-05	CcSEcCtD
Fentanyl—Dermatitis—Methotrexate—psoriasis	1.04e-05	6.27e-05	CcSEcCtD
Fentanyl—Headache—Methotrexate—psoriasis	1.04e-05	6.23e-05	CcSEcCtD
Fentanyl—OPRK1—GPCR ligand binding—CCL20—psoriasis	1.03e-05	0.00512	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—HCAR2—psoriasis	1.01e-05	0.00506	CbGpPWpGaD
Fentanyl—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.88e-06	0.00492	CbGpPWpGaD
Fentanyl—Nausea—Methotrexate—psoriasis	9.82e-06	5.91e-05	CcSEcCtD
Fentanyl—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	9.44e-06	0.00471	CbGpPWpGaD
Fentanyl—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.26e-06	0.00462	CbGpPWpGaD
Fentanyl—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.13e-06	0.00455	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.78e-06	0.00438	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CCL20—psoriasis	8.68e-06	0.00433	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—CD4—psoriasis	8.67e-06	0.00432	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—HCAR2—psoriasis	8.58e-06	0.00427	CbGpPWpGaD
Fentanyl—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.99e-06	0.00398	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL10—psoriasis	7.95e-06	0.00396	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—JUN—psoriasis	7.76e-06	0.00387	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL4—psoriasis	7.73e-06	0.00385	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.56e-06	0.00377	CbGpPWpGaD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.55e-06	0.00376	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	7.47e-06	0.00372	CbGpPWpGaD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.03e-06	0.00351	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—HLA-A—psoriasis	7e-06	0.00349	CbGpPWpGaD
Fentanyl—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.89e-06	0.00343	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—HCAR2—psoriasis	6.84e-06	0.00341	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CCL20—psoriasis	6.62e-06	0.0033	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.4e-06	0.00319	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	6.19e-06	0.00309	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCL20—psoriasis	6.01e-06	0.003	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—HCAR2—psoriasis	5.99e-06	0.00299	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TAGAP—psoriasis	5.93e-06	0.00295	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CCL20—psoriasis	5.8e-06	0.00289	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—NDUFA5—psoriasis	5.54e-06	0.00276	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	5.43e-06	0.00271	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCL20—psoriasis	5.27e-06	0.00263	CbGpPWpGaD
Fentanyl—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	5.22e-06	0.0026	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TAGAP—psoriasis	5.2e-06	0.00259	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—HCAR2—psoriasis	5.07e-06	0.00252	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CCL20—psoriasis	4.91e-06	0.00244	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—CYP2S1—psoriasis	4.71e-06	0.00235	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—IL6—psoriasis	4.69e-06	0.00234	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IFNG—psoriasis	4.67e-06	0.00233	CbGpPWpGaD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.66e-06	0.00232	CbGpPWpGaD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.59e-06	0.00229	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	4.58e-06	0.00228	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCL20—psoriasis	4.45e-06	0.00222	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TAGAP—psoriasis	4.39e-06	0.00219	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.34e-06	0.00217	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.15e-06	0.00207	CbGpPWpGaD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.07e-06	0.00203	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—NDUFA5—psoriasis	4.01e-06	0.002	CbGpPWpGaD
Fentanyl—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	3.87e-06	0.00193	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.64e-06	0.00182	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.58e-06	0.00178	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCL20—psoriasis	3.55e-06	0.00177	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.53e-06	0.00176	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CYP2S1—psoriasis	3.41e-06	0.0017	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CXCL8—psoriasis	3.16e-06	0.00158	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL20—psoriasis	3.11e-06	0.00155	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.08e-06	0.00153	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—TNF—psoriasis	3.02e-06	0.00151	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—NDUFA5—psoriasis	3.02e-06	0.00151	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.01e-06	0.0015	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.81e-06	0.0014	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CXCL8—psoriasis	2.77e-06	0.00138	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.68e-06	0.00134	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL20—psoriasis	2.63e-06	0.00131	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CYP2S1—psoriasis	2.57e-06	0.00128	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CXCL8—psoriasis	2.34e-06	0.00117	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—CARM1—psoriasis	2.3e-06	0.00115	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.99e-06	0.000993	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.96e-06	0.000974	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.92e-06	0.000956	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.86e-06	0.000929	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NDUFA5—psoriasis	1.86e-06	0.000928	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.79e-06	0.000891	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.74e-06	0.000868	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.71e-06	0.000855	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CARM1—psoriasis	1.66e-06	0.000829	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.63e-06	0.000815	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.62e-06	0.000809	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CYP2S1—psoriasis	1.58e-06	0.000789	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1.57e-06	0.000781	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.49e-06	0.000744	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.45e-06	0.000722	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—APOE—psoriasis	1.44e-06	0.000719	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—LEP—psoriasis	1.44e-06	0.000719	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.42e-06	0.000709	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—CAT—psoriasis	1.42e-06	0.000705	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.38e-06	0.000689	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.34e-06	0.00067	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.32e-06	0.00066	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.32e-06	0.000656	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—LEP—psoriasis	1.27e-06	0.000631	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—APOE—psoriasis	1.27e-06	0.000631	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CARM1—psoriasis	1.26e-06	0.000626	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.2e-06	0.0006	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.18e-06	0.000588	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TYK2—psoriasis	1.1e-06	0.000549	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—APOE—psoriasis	1.1e-06	0.000548	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—LEP—psoriasis	1.07e-06	0.000533	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—APOE—psoriasis	1.07e-06	0.000533	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CAT—psoriasis	1.02e-06	0.00051	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—NFKBIA—psoriasis	9.96e-07	0.000497	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TYK2—psoriasis	9.66e-07	0.000481	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CXCL8—psoriasis	9.59e-07	0.000478	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PPARG—psoriasis	9.58e-07	0.000477	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL6—psoriasis	9.12e-07	0.000454	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—JUN—psoriasis	8.91e-07	0.000444	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—NFKB1—psoriasis	8.58e-07	0.000428	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CXCL8—psoriasis	8.41e-07	0.000419	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TYK2—psoriasis	8.16e-07	0.000407	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL6—psoriasis	8e-07	0.000398	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—APOE—psoriasis	7.95e-07	0.000396	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—JUN—psoriasis	7.82e-07	0.00039	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—VEGFA—psoriasis	7.79e-07	0.000388	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CARM1—psoriasis	7.73e-07	0.000385	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CAT—psoriasis	7.72e-07	0.000385	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—STAT3—psoriasis	7.71e-07	0.000384	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—NFKB1—psoriasis	7.52e-07	0.000375	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CXCL8—psoriasis	7.11e-07	0.000354	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PPARG—psoriasis	6.92e-07	0.000345	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—VEGFA—psoriasis	6.83e-07	0.00034	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—STAT3—psoriasis	6.76e-07	0.000337	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL6—psoriasis	6.76e-07	0.000337	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—JUN—psoriasis	6.61e-07	0.000329	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—NFKB1—psoriasis	6.36e-07	0.000317	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—APOE—psoriasis	6e-07	0.000299	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TP53—psoriasis	5.88e-07	0.000293	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—VEGFA—psoriasis	5.77e-07	0.000288	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—STAT3—psoriasis	5.71e-07	0.000285	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL6—psoriasis	5.39e-07	0.000268	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PPARG—psoriasis	5.23e-07	0.00026	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TP53—psoriasis	5.16e-07	0.000257	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CAT—psoriasis	4.76e-07	0.000237	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL6—psoriasis	4.72e-07	0.000235	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TP53—psoriasis	4.36e-07	0.000217	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL6—psoriasis	3.99e-07	0.000199	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—APOE—psoriasis	3.7e-07	0.000184	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PPARG—psoriasis	3.22e-07	0.00016	CbGpPWpGaD
